0.375  -0 (-0.05%)		07-18 16:00
Open: 0.3725 High: 0.375 Volume: 1,157,171		Pre. Close: 0.3752 Low: 0.3713 Market Cap: 22(M)

Short term
Mid term
Targets	6-month :	0.44	1-year :	0.45
Resists	First :	0.37	Second :	0.38
Pivot price	0.37
Supports	First :	0.36	Second :	0.3
MAs	MA(5) :	0.37	MA(20) :	0.37
	MA(100) :	0.36	MA(250) :	0.61
MACD	MACD :	0	Signal :	0
%K %D	K(14,3) :	52.2	D(3) :	57.1
RSI	RSI(14): 52.6
52-week	High :	3.08	Low :	0.22

Price has closed below its short-term moving average. Short-term moving average is currently above mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and NEUTRAL in mid-long term.
[ ELEV ] has closed above bottom band by 43.7%. Bollinger Bands are 83.4% narrower than normal. The narrow width of the bands suggests low volatility as compared to its normal range. The bands have been in this narrow range for 15 bars. This is a sign that the market may be about to initiate a new trend.

If tomorrow:	Open lower	Open higher
High:	0.38 - 0.38	0.38 - 0.38
Low:	0.37 - 0.37	0.37 - 0.37
Close:	0.37 - 0.38	0.38 - 0.38

Elevation Oncology, Inc., a clinical-stage biopharmaceutical company, focuses on developing therapeutics for the treatment of cancer in genomically defined patient populations in the United States. The company's lead program is the seribantumab, an anti-HER3 monoclonal antibody that is in Phase II CRESTONE trial for the treatment of advanced solid tumors harboring a neuregulin-1 fusion. Elevation Oncology, Inc. was incorporated in 2019 and is based in New York, New York.

Wed, 02 Jul 2025
Elevation Oncology Terminates License Agreement with CSPC - TipRanks

Mon, 09 Jun 2025
Elevation Oncology Enters into Agreement to Be Acquired by Concentra Biosciences for $0.36 in Cash per Share Plus a Contingent Value Right - PR Newswire

Mon, 09 Jun 2025
ELEV Stock Alert: Halper Sadeh LLC Is Investigating Whether the Sale of Elevation Oncology, Inc. Is Fair to Shareholders - Business Wire

Fri, 16 May 2025
William Blair Remains a Buy on Elevation Oncology (ELEV) - The Globe and Mail

Fri, 21 Mar 2025
Elevation Oncology Plunges 42% on Ending Development of Lead Drug - Zacks Investment Research

Fri, 21 Mar 2025
Elevation Oncology downgraded as it halts lead asset on disappointing trials - Yahoo Finance

Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly.	Outperform
Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS).	Underperform
Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows.	Outperform
Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit.	Underperform
Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency.	Underperform
Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn.	Underperform

Exchange: NASDAQ
Sector: Healthcare
Industry: Biotechnology
Shares Out	59 (M)
Shares Float	44 (M)
Held by Insiders	0.3 (%)
Held by Institutions	57.3 (%)
Shares Short	3,040 (K)
Shares Short P.Month	4,430 (K)

EPS	-0.82
EPS Est Next Qtrly	0
EPS Est This Year	0
EPS Est Next Year	0
Book Value (p.s.)	0.79
Profit Margin	0 %
Operating Margin	0 %
Return on Assets (ttm)	-29.9 %
Return on Equity (ttm)	-78.4 %
Qtrly Rev. Growth	0 %
Gross Profit (p.s.)	0
Sales Per Share	0
EBITDA (p.s.)	-0.78
Qtrly Earnings Growth	0 %
Operating Cash Flow	-40 (M)
Levered Free Cash Flow	-22 (M)

PE Ratio	-0.47
PEG Ratio	0
Price to Book value	0.47
Price to Sales	0
Price to Cash Flow	-0.57

Dividend	0
Forward Dividend	0
Dividend Yield	0%
Dividend Pay Date	Invalid DateTime.
Ex-Dividend Date	Invalid DateTime.